Share-based Compensation (Tables)

12 Months Ended

Jun. 30, 2015

Share-based Compensation

Schedule of weighted average assumptions used to estimate fair values of the stock options granted and the estimated annual forfeiture rates used to recognize the associated compensation expense and the weighted average fair value of the options granted

	June 30, 2015			June 30, 2014			June 30, 2013
Risk-free interest rate	1.7		%	2.1		%	1.0		%
Expected volatility	52.1		%	62.8		%	61.6		%
Expected dividend yield	0.0		%	0.0		%	0.0		%
Forfeiture rate	6.5		%	7.5		%	7.5		%
Expected term (in years)	5.5 years			5.9 years			6.1 years
Weighted average fair value	$	17.73		$	8.55		$	2.53

Summary of stock option award activity

							Weighted
			Weighted-				Average
			Average		Aggregate		Remaining
			Exercise		Intrinsic		Contractual
(In thousands, except for weighted average price and life data)	Awards		Price		Value		Life (yrs.)
Outstanding at July 1, 2012	2,747		$	6.42
Granted	565		4.30
Exercised	(511	)	5.44		$	1,825
Forfeited, expired or repurchased	(482	)	8.39
Outstanding at June 30, 2013	2,319		5.71
Granted	780		13.90
Exercised	(783	)	6.41		$	24,375
Forfeited, expired or repurchased	(111	)	6.49
Outstanding at June 30, 2014	2,205		7.84
Granted	513		36.71
Exercised	(665	)	6.47		$	33,201
Forfeited, expired or repurchased	(78	)	18.33
Outstanding at June 30, 2015	1,975		$	15.39	$	86,983	7.2
Vested and expected to vest at June 30, 2015	1,910		$	15.01	$	84,865	7.1
Exercisable at June 30, 2015	858		$	5.97	$	45,879	5.5

Summary of nonvested restricted stock awards

(In thousands)	Awards		Weighted Average Grant - date Fair Value		Aggregate Intrinsic Value
Non-vested at July 1, 2012	74		$	6.94
Granted	38		5.06
Vested	(110	)	6.30		$	491
Forfeited	(2	)	6.94
Non-vested at June 30, 2013	—		—
Granted	269		24.07
Vested	(252	)	23.45		$	10,440
Forfeited	(1	)	24.48
Non-vested at June 30, 2014	16		34.01
Granted	103		37.97
Vested	(14	)	36.06		$	664
Forfeited	(7	)	36.59
Non-vested at June 30, 2015	98		$	37.83

Schedule of allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item

	For Fiscal Year Ended June 30,
(In thousands)	2015		2014		2013
Selling, general and administrative	$	5,145	$	7,388	$	1,206
Research and development	523		675		99
Cost of sales	729		963		172
Total	$	6,397	$	9,026	$	1,477
Tax benefit at statutory rate	$	2,159	$	3,375	$	169